



Patent

Attorney's Docket No. 032751-049

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Olivier MEYER

Application No.: 09/880,038

Filed: June 14, 2001

For: COMBINATION PRODUCT
INTENDED FOR CARRYING OUT A
CYTOTOXIC TREATMENT, IN
PARTICULAR AN ANTITUMOR
TREATMENT, IN A MAMMAL

Group Art Unit: 1645

Examiner: Unassigned

Confirmation No.: 7218

RECEIVED
AUG 05 2002
TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


- ☒ [X] No additional fee for submission of an IDS is required.
- ☐ [] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ [] Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ [] A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By: 
Teresa Stanek Rea
Registration No. 30,427

Date: August 1, 2002



Patent
Attorney's Docket No. 032751-049

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|-----------------------------|---|------------------------|
| In re Patent Application of |) | |
| Olivier MEYER |) | Group Art Unit: 1645 |
| Application No.: 09/880,038 |) | Examiner: Unassigned |
| Filed: June 14, 2001 |) | Confirmation No.: 7218 |
| For: COMBINATION PRODUCT |) | |
| INTENDED FOR CARRYING OUT A |) | |
| CYTOTOXIC TREATMENT, IN |) | |
| PARTICULAR AN ANTITUMOR |) | |
| TREATMENT, IN A MAMMAL |) | |

RECEIVED
AUG 05 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicant hereby submits the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore under 37 C.F.R. § 1.97(b) no fee or statement is required.

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than 30 (thirty) days prior to the filing of this Information Disclosure Statement.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____

Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: August 1, 2002